Triheptanoin

428.61

428.60

210-647-2

2P6O7CFW5K

A - Alimentary tract and metabolism

2915900090

78.9

7.73

colourless liquid

0.904 g/cm³ @ Temp: 100 °C

178 °C @ Press: 0.3 Torr

195.5±19.6 °C

1.457

LD50 intravenous in mouse: 320mg/kg

1

38

Xi

Stable. Incompatible with strong oxidizing agents.

P264, P273, P280, P302+P352, P321, P332+P313, P362, P391, P501

H315

|Warning|H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]|P264, P273, P280, P302+P352, P321, P332+P313, P362, P391, and P501|Aggregated GHS information provided by 103 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Triheptanoin is approximately 80% protein bound in plasma, likely serum albumin.

Triheptanoin is a medium chain triglyceride indicated to provide calories and fatty acids to treat long chain fatty acid oxidation disorders (lc-FAODs).|FDA Label

Triheptanoin is a source of medium chain fatty acids for patients with lc-FAODs. It has a moderate duration of action and a wide therapeutic window. Patients should be counselled regarding the risk of feeding tube dysfunction and intestinal malabsorption due to pancreatic insufficiency.

A single 0.3 g/kg dose of triheptanoin reaches a C_max of 178.9 µmol/L, with a T_max 0.5 h, and an AUC of 336.5 µmol\*h/L. A single 0.4 g/kg dose of triheptanoin reaches a C_max of 259.1 µmol/L, with a T_max 0.8 h, and an AUC of 569.1 µmol\*h/L.|Triheptanoin is minimally eliminated in the urine.|A single dose of 0.3 g/kg results in a mean apparent clearance of 6.05 L/h/kg for heptanoate. A single dose of 0.4 g/kg results in a mean apparent clearance of 4.31 L/h/kg for heptanoate.

Triheptanoin is hydrolysed to heptanoate, which can be further metabolized to β-hydroxypentanoate or β-hydroxybutyrate.

Due to multiple peak concentrations of the heptanoate metabolite, the half life of triheptanoin could not be determined.

Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with lc-FAODs treated with triheptanoin experienced improvements in hypoglycemia, cardiomyopathy, and rhabdomyolysis.

glyceroltriheptanoate

Heptanoic acid, 1,1',1''-(1,2,3-propanetriyl) ester: ACTIVE|PMN - indicates a commenced PMN (Pre-Manufacture Notices) substance.

Human drugs -> Rare disease (orphan)|Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients|Cosmetics -> Skin conditioning; Surfactant